Eddie is mainly responsible for the deal sourcing, due diligence and operations in Rimonci, and he is also highly involved in the post investment management process to help the portfolio companies to develop in China. Prior to Rimonci, Eddie has already been working in investment industry for years. His personal career started from the financial investment area, where he was focused on the investment as well as fundraising in one of the top private equity investment company in China. After that, Eddie switched to strategic investment and worked as the general manager of the group strategic investment department in one of the Chinese comprehensive IT group, mainly in charge of the group investment, M&A and overseas business development. Eddie has both the B.S in Economics and MBA degrees from Tsinghua University, and also MBA from Hebrew University. He is fluent in English and has rich oversea life experience. During the college, Eddie used to study and work in Korea, India, Uganda, Kenya, and Dubai for years, which helped him to build up the skills for cross culture communications.

Richel is Founder and CEO of Rimonci Capital,the member of the fund investment committee. She is responsible for Rimonci overall strategies and transactions control. Prior to founding Rimonci at start of 2016, Richel served as CEO of a comprehensive IT group in China with 1.5 billion USD in sales, and also Executive Director of HK listed company and chairman of Shanghai listed company in this group. During her tenure, Richel was responsible for different business investment and operation, especially electronics, IC substrate, enterprise software, system integration and finally the overall management of the whole group. With more than 17 years of investment, mergers and acquisitions, business operation and management experience, she has distinguished tracking record on setting up new business and grow business from earlier stage to mature stage either by organic growth or through investment. Richel also have abundant cross-board working experience, competent for multiple board governance structure and management. Richel earned MS degree in economics and BS degree in engineering, also Received Senior Leadership Training Certification from Yale School of Management. Acquired the certification of Eye, Ear, Nose & Throat Innovation by Biodesign of Stanford and Byers Eye Institute. With the qualifications for securities and funds in China. Be the member of Singapore National Eye Center Ophthalmic Technologies Incubator Venture Capital advisory panel.

Rina is partner & BD VP of Rimonci, she is responsible for BD development, post- investment management and public relationships. Prior to joining Rimonci, she used to work for the Embassy of Israel as senior trade officer for 6 years. She helped Israeli companies in the investment,ICT and homeland security industry to develop their businesses in China, and also helped distinguished Chinese companies find innovative technology and M&A opportunities in Israel. She did great bridge job for government officials, entrepreneurs and senior executives both from China and Israel. Before working for embassy, she worked for Alcatel-Lucent and Intel in business development for more than 10 years. Rina is passionate, responsible and considerate. She has an MBA from Cardiff University,United Kingdom. Rina is very fluent at English and having the qualifications for securities and funds in China.

Wei Wei, CPA, CTA and senior florist, is in charge of finance and compliance management in Rimonci. Wei has accumulated rich experience in strategic advisory and corporate finance during her service as assistant manager in KPMG, senior strategy manager and executive assistant to CEO of a multi-billion-dollar-asset company, and financial director in a comprehensive finance group. Wei has an MBA from IESE Business School and double-bachelor in Financial Management and English from Tianjin University. She has advanced professional proficiency in English, and business proficiency in Spanish and Korean.

David is responsible for scouting deals, conducting due diligence, and assisting in all the work related to Aier Rimonci Accelerator. Prior to joining Rimonci Capital, David worked on eye movement research at NYU Langone Medical Center, and developed an automatic software for the quantitatively analysis of eye movements. David also worked at an international hedge fund, where he applied signal processing techniques to implement clustering, and design trading strategies. David received B.E. degree in Mechanical Engineering and Automation from Shanghai University, and PhD degree in Electrical Engineering from New York University, his expertise includes digital signal processing, machine learning, eye movement analysis, and quantitative trading.

Mengtian Kang, MD & PhD, is mainly responsible for clinical assessment in Rimonci and serves as an ophthalmologist in Beijing Tongren Hospital, Capital Medical University. Her research mainly focuses on refractive error and anterior ocular diseases. She published over 40 papers, among which 7 were published with her as the first author. She has more than 8 years of experience in clinical trial management, epidemiology study and RCT design.She was recognized as “Young Elite Scientists Sponsorship Program” of China Association for Science and Technology(CAST) in 2019 and was awarded The first prize of Science Technology Improvement Award for“Myopia prevention and technology” project, and Science Research Achievement Award in Colleges and Universities, China(2019).

Cynthia, MD & PhD, associate professor, mainly responsible for Rimonci medical affairs. Cynthia has more than 15 years of experience in ophthalmic medical devices (MD) and medications research, including molecular biology, animal model experiments and clinical trials. She is familiar with the R&D, registration inspection, pre-clinical evaluation, clinical trials design and analysis of ophthalmic Class III MD. Cynthia graduated from Zhongshan Ophthalmic Center of Sun Yat-sen University and participated a joint supervision scheme at McGill University during PhD training. She used to work at Peking University People’s Hospital, and a MedTech startup specialized in active implantable medical devices and medical artificial intelligence. Cynthia has published more than 80 peer-review articles in academic journals (40+ published as first or corresponding authors), including Cell Death DIS, J Biol Chem, J Pharmaceutical Exp Ther, IOVS, Retina, BJO, Mediators Inflamm, etc. She has been recognized as High Caliber Personnel in Guangdong Province and Shenzhen, and the Beijing Nova Star in Science and Technology.

TEAM

Rina

Partner & CAO

Eddie

Co-Founder & COO

Richel

Founder & CEO

Wei Wei

Partner & CFO

Cynthia

CMO

David

Partner

Mengtian Kang

Ophthalmologist